首页> 外文期刊>HPB Surgery >Unresectable Malignant Biliary Obstruction: Treatment by Self-Expandable Biliary Endoprostheses
【24h】

Unresectable Malignant Biliary Obstruction: Treatment by Self-Expandable Biliary Endoprostheses

机译:不可切除的恶性胆道梗阻:自膨式胆道内支架治疗

获取原文
       

摘要

The primary goal in the treatment of malignant obstruction is the relief of jaundice. Although operativebiliary bypass is a reliable method of palliation, nonoperative palliation may be desirable in selected patients.We report our experience with forty-eight self expandable metallic biliary endoprostheses (Wallstent)percutaneously placed in 35 patients with irresectable malignant biliary obstruction. In twelve patients more than one stent was necessary to bridge the entire length of the biliary stenosis. The obstruction was due to primary tumors in 14 and to lymph node metastases in 12. In nine patients transanastomotic stents were placed after previous bilioenteric anastomosis because of malignant obstruction. Complications occurred in 11 patients (31.4%), and five patients died within 30 days of stent placement (14.3%). The mean stent patency to date of patients discharged is 6.1 months, and the mean survival 7.2 months. Follow up data is available for 29 patients, and excellent palliation was achieved for more than 75% of the survival time in 22 (76%). Seven patients have had documented stent occlusion requiringfurther intervention (24%).In this selected group of patients, the results of percutaneous self-expandable stents are encouraging.However, our data does not support the initial reports of self-expandable endoprostheses that suggest animproved result compared to conventional plastic stents. A randomized study using either expandablestents as compared to operative biliary enteric bypass is necessary.
机译:治疗恶性梗阻的主要目标是减轻黄疸。尽管术中胆道旁路术是一种可靠的缓解方法,但对于某些患者,可能不希望进行术中缓解。我们报道了35例无法切除的恶性胆道梗阻患者经皮自植入48例自扩张金属胆管假体(Wallstent)的经验。在十二名患者中,需要一个以上的支架来弥合整个胆道狭窄。梗阻是由于14例原发肿瘤和12例淋巴结转移引起的。在9例患者中,由于恶性梗阻,在先前的双肠吻合术后放置了经肛门吻合的支架。 11例患者发生并发症(31.4%),五名患者在置入支架后30天内死亡(14.3%)。迄今为止,患者平均支架通畅时间为6.1个月,平均生存时间为7.2个月。有29位患者的随访数据,其中22位(76%)的生存时间超过75%达到了极好的缓解。已有7名患者记录了需要进一步干预的闭塞支架(24%)。在这部分患者中,经皮自扩张支架的结果令人鼓舞,但我们的数据不支持表明自扩张支架的初步报道结果与传统的塑料支架相比。一项与手术性胆道肠旁路术相比,使用可扩张支架的随机研究是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号